A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger, Anne Katrin
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. [electronic resource] - BMC cancer Mar 2012 - 108 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
1471-2407
10.1186/1471-2407-12-108 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--therapeutic use
Cetuximab
Colorectal Neoplasms--diagnostic imaging
ErbB Receptors--antagonists & inhibitors
Female
Fluorodeoxyglucose F18--pharmacokinetics
Humans
Male
Positron-Emission Tomography
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals--pharmacokinetics
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. [electronic resource] - BMC cancer Mar 2012 - 108 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
1471-2407
10.1186/1471-2407-12-108 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--therapeutic use
Cetuximab
Colorectal Neoplasms--diagnostic imaging
ErbB Receptors--antagonists & inhibitors
Female
Fluorodeoxyglucose F18--pharmacokinetics
Humans
Male
Positron-Emission Tomography
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals--pharmacokinetics